Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes? Response

被引：0
|
作者：
Bennett, Melanie E. [1 ]
Calkins, Monica E. [2 ,3 ]
Dickerson, Faith [4 ]
Kreyenbuhl, Julie [1 ]
Medoff, Deborah [1 ]
机构：
[1] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD USA
[2] Univ Penn, Perelman Sch Med, Penn Early Intervent Ctr PE HeadsUp, Dept Psychiat,Neurodev & Psychosis Sect, Philadelphia, PA USA
[3] Univ Penn, Perelman Sch Med, Dept Psychiat, Neurodev & Psychosis Sect, Philadelphia, PA USA
[4] Sheppard Pratt, Dept Psychol, Baltimore, MD USA
来源：
SCHIZOPHRENIA RESEARCH | 2024年 / 270卷
关键词：
D O I：
10.1016/j.schres.2024.06.012
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [41] Exploring the impact of type 2 diabetes and glucose-lowering drugs on gut microbiome dynamics
    Hafiz Muhammad Adnan Tariq
    Nayyab Younas Khan
    Haseeb Manzoor
    Masood Ur Rehman Kayani
    Discover Medicine, 2 (1):
  • [42] Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease
    Inzucchi, Silvio E.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (01) : 137 - +
  • [43] Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes
    Rathmann, Wolfgang
    Strassburger, Klaus
    Bongaerts, Brenda
    Bobrov, Pavel
    Kuss, Oliver
    Muessig, Karsten
    Markgraf, Daniel F.
    Szendroedi, Julia
    Herder, Christian
    Roden, Michael
    DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 866 - 873
  • [44] The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes
    Kodera, Ryo
    Shikata, Kenichi
    Nakamura, Akihiko
    Okazaki, Satoru
    Nagase, Ryo
    Nakatou, Tatsuaki
    Haisa, Shigeru
    Hida, Kazuyuki
    Miyashita, Katsuhiro
    Makino, Hirofumi
    INTERNAL MEDICINE, 2017, 56 (06) : 605 - 613
  • [45] New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies
    Hsiao, Fu-Chih
    Yen, Kun-Chi
    Chao, Tze-Fan
    Chen, Shao-Wei
    Chan, Yi-Hsin
    Chu, Pao-Hsien
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (09): : 2493 - 2499
  • [46] Personalized glucose-lowering effect of chiglitazar in type 2 diabetes
    Huang, Qi
    Zou, Xiantong
    Chen, Yingli
    Gao, Leili
    Cai, Xiaoling
    Zhou, Lingli
    Gao, Fei
    Zhou, Jian
    Jia, Weiping
    Ji, Linong
    ISCIENCE, 2023, 26 (11)
  • [47] Glycemic control in Kuwaiti diabetes patients treated with glucose-lowering medication
    Abdullah, Ameera
    Alkandari, Abdullah
    Longenecker, Joseph C.
    Devarajan, Sriraman
    Alkhatib, Ahmad
    Al-Wotayan, Rihab
    Al-Duwairi, Qais
    Tuomilehto, Jaakko
    PRIMARY CARE DIABETES, 2020, 14 (04) : 311 - 316
  • [48] Canada Welcomes a Novel Class of Oral Glucose-Lowering Drugs People with Type 2 Diabetes
    Lau, David C. W.
    CANADIAN JOURNAL OF DIABETES, 2014, 38 (04) : 219 - 220
  • [49] Real world evidence of clinical predictors of glycaemic response to glucose-lowering drugs among Chinese with type 2 diabetes
    Wu, Hongjiang
    Lau, Eric S. H.
    Yang, Aimin
    Fan, Baoqi
    Ma, Ronald C. W.
    Kong, Alice P. S.
    Chow, Elaine
    So, Wing-Yee
    Chan, Juliana C. N.
    Luk, Andrea O. Y.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2023, 39 (04)
  • [50] UTILIZATION TRENDS OF GLUCOSE-LOWERING DRUGS FOR TYPE 2 DIABETES IN OLDER ADULTS WITH AND WITHOUT DEMENTIA
    Gopalakrishnan, Chandrasekar
    Kim, Dae
    Patorno, Elisabetta
    INNOVATION IN AGING, 2022, 6 : 468 - 469
12345